Table 1 Demographic characteristics of the subjects in the clinical trial

From: The role of FGF-2 in smoke-induced emphysema and the therapeutic potential of recombinant FGF-2 in patients with COPD

 

Control group (n = 6)

FGF-2 group (n = 6)

p-valuea

Age (year)

66.7 ± 11.7

63.0 ± 10.5

0.39

Male (%)

6 (100)

5 (83)

0.30

BMI (kg/m2)

21.8 ± 3.3

23.3 ± 3.6

0.39

Smoking pack-years

45.0 ± 10.9

32.0 ± 17.3

0.24

Pulmonary function tests

 FEV1 (%)

41.6 ± 9.19

49.7 ± 7.4

0.24

 FVC (%)

63.6 ± 10.5

74.2 ± 15.2

0.13

  1. FGF-2 fibroblast growth factor-2, BMI body mass index, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity
  2. aStatistical differences were tested by Pearson’s chi-square test
Back to article page